Novo Nordisk A/S was the biggest leader among large stocks during the session, gaining 5.8%, and DNO ASA gained 5.4%. Carlsberg A/S Series A rounded out the top three leaders on Friday, with shares ...

Sweden’s BioArctic today revealed that the US Federal Trade Commission (FTC) has cleared the proposed deal with Bristol Myers ...

Eisai announces Leqembi sales reaches €200 million; BioArctic to receive €10 million payment: Stockholm, Sweden Wednesday, February 19, 2025, 14:00 Hrs [IST] BioArctic AB’s ...

BioArctic AB's (publ) partner Eisai has notified BioArctic that the first sales milestone according to the licensing agreement has been reached. The milestone was reached as sales of Leqembi reached ?

Nordic stocks gained Monday, with the OMX Nordic 40 Index rising 1.1%. Saab AB Series B was the biggest leader among large stocks during the session, surging 16.2%, and BioArctic AB Series B rose 9.1% ...

BioArctic signed the first deal for its “brain transporter” with Bristol Myers Squibb late last year. The deal is worth up to $1.4bn and allows the US drugmaker to start trials using the technology to ...

BioArctic AB (BRCTF) reports significant licensing deals and growing market demand, while navigating regulatory challenges and increased expenses.

Pioneering license agreement with BrainTransporter signed with BMS worth up to USD 1.35 billion plus royalties Events during the fourth quarter 2024 The Australian Medicines Agency (TGA) decided not ...

Pagaya Technologies Ltd. ("Pagaya", the "Company" or "we"), a global technology company delivering artificial intelligence infrastructure for the financial ecosystem, today announced financial results ...

BioArctic, with a current market capitalization of $158.45 million, reported a robust performance for the fourth quarter of 2024, achieving net revenues of $101 million, with a significant increase in ...

Shares of BioArctic AB (STO:BIOA-B) climbed 5% as the company reported its full-year results, which were largely in line with ...